BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis
- 1Department of Obstetrics and Gynecology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Abstract
Background: Aberrant histone lactylation is emerging as a pivotal player in tumorigenesis. However, its role in epithelial ovarian cancer (EOC) has not been fully elucidated to date.
Methods: Histone lactylation levels were detected using western blotting and immunohistochemistry in EOC and their prognostic value was evaluated. By integrating CUT&Tag and RNA-seq data, we pinpointed Ubiquitin-conjugating E2 enzyme variant 1(Ube2v1) as the crucial gene regulated by Histone H4K12 lactylation (H4K12la). The role of H4K12la on enhancing Ube2v1 expression was confirmed through RT-PCR, western blotting, ChIP, and dual-luciferase reporter assays. Target proteins interacting with and regulated by Ube2v1 were identified using IP-MS and validated by Co-IP. A histone modification compound library was used to screen potential modulators of H4K12la. MALDI-TOF/TOF MS was used to detect in vitro enzymatic products to investigate the potential lactylation activity of BRD4.
Results: H4K12la was significantly elevated in EOC tissues and associated with poor patient survival. We identified Ube2v1 as a key target gene activated by H4K12la. Ube2v1 promoted EOC cell proliferation and inhibited apoptosis by forming a complex with Ubc13 to catalyze the K63-linked ubiquitination and subsequent autophagic degradation of DDX3X. Through a targeted compound screen, we discovered that BET inhibitors, especially inhibitors that target BRD4 via the PROTAC approach, could significantly downregulate the level of H4K12la. Crucially, our findings suggest that BRD4 might play a direct role in modulating H4K12 lactylation. The expression levels of BRD4, H4K12la, and Ube2v1 were positively correlated in clinical EOC samples and ovarian cancer cell lines.
Conclusion: Our study uncovers a previously unrecognized function of BRD4 in regulating histone lactylation and delineates the oncogenic BRD4/H4K12la/Ube2v1/DDX3X axis in EOC. These findings not only provide a profound mechanistic insight into EOC progression but also firmly establish the therapeutic rationale for targeting BRD4, via PROTAC inhibitors, in the treatment of EOC.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08434-1.
Related
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
- Histone Lactylation Drives WNK1 Expression to Promote Esophageal Squamous Cell Carcinoma Progression Through Histone H3 Ser10 Phosphorylation
- NEURL1-mediated K63-ubiquitination of SLC40A1 drives ferroptosis resistance in pathological scars: Therapeutic targeting via autophagy-activating microneedles.
- Chrysanthemum Morifolium-Derived Nanovesicles Reduce Lactate-Associated Histone Lactylation and Modulate Microglia-Mediated Neuroinflammation in Sepsis-Associated Encephalopathy.
- METTL7B-Mediated m6A Modification of PLEKHA4 Suppresses Ferroptosis via Reducing AURKA Ubiquitination to Promote Papillary Thyroid Cancer Progression.
BibTeX
@article{jiang2026brd4mediated,
title = {{BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis}},
author = {Yahui Jiang and Tianjiao Lyu and Tianyu Zhou and Chongying Zhu and Weiwei Feng},
journal = {Journal of Translational Medicine},
year = {2026},
month = jun,
doi = {10.1186/s12967-026-08434-1},
url = {https://doi.org/10.1186/s12967-026-08434-1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis
AU - Yahui Jiang
AU - Tianjiao Lyu
AU - Tianyu Zhou
AU - Chongying Zhu
AU - Weiwei Feng
PY - 2026
DA - 2026/06/29
JO - Journal of Translational Medicine
DO - 10.1186/s12967-026-08434-1
UR - https://doi.org/10.1186/s12967-026-08434-1
AB - Background: Aberrant histone lactylation is emerging as a pivotal player in tumorigenesis. However, its role in epithelial ovarian cancer (EOC) has not been fully elucidated to date. Methods: Histone lactylation levels were detected using western blotting and immunohistochemistry in EOC and their prognostic value was evaluated. By integrating CUT&Tag and RNA-seq data, we pinpointed Ubiquitin-conjugating E2 enzyme variant 1(Ube2v1) as the crucial gene regulated by Histone H4K12 lactylation (H4K12la). The role of H4K12la on enhancing Ube2v1 expression was confirmed through RT-PCR, western blotting, ChIP, and dual-luciferase reporter assays. Target proteins interacting with and regulated by Ube2v1 were identified using IP-MS and validated by Co-IP. A histone modification compound library was used to screen potential modulators of H4K12la. MALDI-TOF/TOF MS was used to detect in vitro enzymatic products to investigate the potential lactylation activity of BRD4. Results: H4K12la was significantly elevated in EOC tissues and associated with poor patient survival. We identified Ube2v1 as a key target gene activated by H4K12la. Ube2v1 promoted EOC cell proliferation and inhibited apoptosis by forming a complex with Ubc13 to catalyze the K63-linked ubiquitination and subsequent autophagic degradation of DDX3X. Through a targeted compound screen, we discovered that BET inhibitors, especially inhibitors that target BRD4 via the PROTAC approach, could significantly downregulate the level of H4K12la. Crucially, our findings suggest that BRD4 might play a direct role in modulating H4K12 lactylation. The expression levels of BRD4, H4K12la, and Ube2v1 were positively correlated in clinical EOC samples and ovarian cancer cell lines. Conclusion: Our study uncovers a previously unrecognized function of BRD4 in regulating histone lactylation and delineates the oncogenic BRD4/H4K12la/Ube2v1/DDX3X axis in EOC. These findings not only provide a profound mechanistic insight into EOC progression but also firmly establish the therapeutic rationale for targeting BRD4, via PROTAC inhibitors, in the treatment of EOC. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08434-1.
SN - 1479-5876
ER -